Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapore’s Bioprocessing Technology Ins...
June 28 2021 - 2:00AM
Business Wire
Project Explores LC-MS Data Analytics Methods
to Rapidly Characterize Complex Biomolecules
NEWS SUMMARY:
- Waters expands collaboration with Bioprocessing Technology
Institute, A*STAR into new areas meant to accelerate bioprocessing
and bioinformatics research.
- Projects include developing analytical workflows for nucleic
acid therapeutic products and bioinformatics research to deliver
robust and accurate identification for a variety of
biomolecules.
- Researchers seek to improve the speed and accuracy of
analytical workflows to help reduce costs, mitigate risks, and
accelerate production of biologics.
Waters Corporation (NYSE:WAT) today announced
an expansion of its joint work with the Bioprocessing Technology
Institute (BTI), a research institute of Singapore's Agency for
Science, Technology and Research (A*STAR). Among their new
collaborative projects, Waters and BTI have started work on
applying analytics that can rapidly identify and visualize complex
molecules within glycomics and metabolomics data to help ensure
overall safety, accuracy, and speed of biologics manufacturing.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210627005019/en/
Waters and BTI are engaging in data analytics research meant to
eliminate a major bottleneck in the characterization of
biopharmaceuticals, namely the identification and quantitation of
complex biomolecules such as released N- and O- glycans and
metabolites that influence therapeutic function. Isomerism of both
glycans and metabolites is particularly troublesome and can be
tackled using Waters’ advanced instruments. However, because the
data generated is massive, advanced bioinformatics approaches and
machine learning techniques are needed to deliver robust and
accurate identification for these and other biomolecules to
overcome time-consuming and expensive conventional methods and
current analytical software that cannot adequately interpret or
visualize the data.
As part of the project, Waters will contribute scientific
expertise and the use of Waters instruments including the SYNAPT™
series mass spectrometry system along with a BioAccord™ LC-MS
System. The SYNAPT instrument features ion mobility mass
spectrometry technology to provide complete characterization of
complex compounds and molecules. The BioAccord system can be used
to monitor product quality attributes in real time that can affect
efficacy and safety of innovator drugs and biosimilars.
“Complex structural analyses of a molecule may hold the key to
the development of novel therapies, including biologics and cell
& gene therapies. The understanding of complex glycan and
isomeric compound structures is largely constrained by the ability
to rapidly and accurately analyze these structures from raw mass
spectrometry data,” said Associate Professor Andre Choo, Deputy
Executive Director of BTI. “Leveraging BTI’s deep domain expertise
in bioprocessing technologies and advanced bioanalytical
capabilities, BTI and Waters will develop methods that combine data
analytics with extensive bioinformatics libraries to ease complex
data annotation. Our aim is to make data interpretation easier and
faster for scientists to accelerate discovery, for conventional
biologics and novel therapeutics.”
“Our work with BTI spans multiple successful collaborations in
the realm of glycomics and bioprocessing research,” said David
Curtin, Vice President of Asia Pacific, Waters Corporation. “They
are pioneers in biomanufacturing innovation in Singapore with
world-class expertise in bioprocess science and engineering. This
work aims to help biotherapeutic manufacturers with at-line or
in-line measurements of complex molecules to identify issues
quickly during routine production and reduce costs or frequency of
failed batches.”
First established in 2014, Waters’ collaborative relationship
with BTI has focused on evaluating the performance of a new
N-linked glycan label aimed at biopharmaceutical applications, the
GlycoWorks™ RapiFluor-MS™ Glycan Kit, and its complete workflow –
from sample preparation to analysis – for glycosylation
profiling.
Additional Resources
- Learn more about Bioprocessing Technology Institute (BTI), a
research institute of A*STAR
- See previous news releases from Waters & BTI from 2016 and
2017
- Connect with Waters via LinkedIn, Twitter, and Facebook
About Waters Corporation (https://www.waters.com)
Waters Corporation (NYSE:WAT), the world's leading specialty
measurement company, has pioneered chromatography, mass
spectrometry, and thermal analysis innovations serving the life,
materials, food and environmental sciences for more than 60 years.
With more than 7,400 employees worldwide, Waters operates directly
in 35 countries, including 14 manufacturing facilities, and with
products available in more than 100 countries.
Waters, SYNAPT, BioAccord, GlycoWorks and RapiFlour-MS are
trademarks of Waters Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210627005019/en/
Queenie Ng Waters Corporation Asia-Pacific queenie_ng@waters.com
+65 9150 2523
Kevin Kempskie Waters Corporation, USA pr@waters.com +1 508 482
2814
Waters (NYSE:WAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Waters (NYSE:WAT)
Historical Stock Chart
From Sep 2023 to Sep 2024